A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia
Latest Information Update: 05 May 2022
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Lundbeck A/S; Merck & Co
Most Recent Events
- 29 Jan 2010 New trial record